


RECEIVED

Sheet 1 of 2

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.462C4APPLICATION NO.
09/636,801

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS
Jennifer L. Mitcham et al.FILING DATE
August 10, 2000GROUP ART UNIT
1631

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
AB						


OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

MKB	AC	Bookman et al., "Biological therapy of ovarian cancer: Current directions," <i>Seminars in Oncology</i> , 25(3):381-396. 1998
	AD	Gillespie et al., "Mage, Bage and Gage: Tumour antigen expression in benign and malignant ovarian tissue," <i>British Journal of Cancer</i> , 78(6):816-821, September, 1998.
	AE	Heller et al., "Discovery and analysis of inflammatory disease-related genes using cDNA microarrays," <i>Proc. Natl. Acad. Sci. USA</i> 94:2150-2155, March, 1997.
	AF	Ishikawa et al., "Prediction of the coding sequence of unidentified human genes. The complete sequence of 100 new cDNA clones from brain which can code for large proteins i vitro," <i>DNA Res.</i> , 5:169-176, 1998.
	AG	Jin et al., "Human T cell leukemia virus type 1 oncoprotein tax targets the human mitotic checkpoint protein MAD1," <i>Cell</i> 93:81-91, April 3, 1998.
	AH	Köhler et al., "Immotherapy of Ovarian Carcinoma with the Monoclonal Anti-Idiotypic Antibody ACA125 - Results of the Phase LB Study," <i>Gebrutshilfe und Fraenheilkunde</i> , 58(4):180-186, April 1998 + (English Abstract).
	AI	Ma et al., "Use of encapsulated single chain antibodies for induction of anti-idiotypic humoral and cellular immune responses," <i>Journal of Pharmaceutical Sciences</i> , 87(11):1375-1378, November, 1998.
MKB	AJ	Parker et al., "Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains," <i>The Journal of Immunology</i> 152(1):163-175, January 1, 1994.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.462C4		APPLICATION NO. 09/636,801	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Jennifer L. Mitcham et al.			
				FILING DATE August 10, 2000			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
BA							
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
BB							
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
MKZ	BC	Peoples et al., "Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides," <i>Annals of Surgical Oncology</i> , 5(8):743-750, December, 1998.					
pkz	BD	Schena et al., "Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes," <i>Proc. Natl. Acad. Sci.</i> , 93:10614-10619, October, 1996.					
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
EXAMINER				DATE CONSIDERED			
MKZ				8/14/01			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							